Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECTAR: Fostamatinib in Hospitalized COVID-19
NCT05593770Phase 3Terminated
- Sponsor
- NEAT ID Foundation
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of fostamatinib in coronavirus disease 2019 (COVID-19), sponsored by NEAT ID Foundation. Started Oct 2022; status: terminated.
02
Drugs
fostamatinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05593770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593770.